Coherus Oncology, Inc.
For the period ended Dec 31, 2024. Filed Mar 17, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 17, 2025
CHRS$0.82+6.2%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
| | | | | | | |
|---|---|---|---|---|---|---|
| · · December 31, | ||||||
| · · 2024 · 2023 | ||||||
| Assets · · · | ||||||
| Current assets: · · · | ||||||
| Cash and cash equivalents | | $125,987 | | $102,891 | ||
| Investments in marketable securities | | | — | | | 14,857 |
| Trade receivables, net | | 111,324 | | 260,522 | ||
| TSA receivables, net (Note 6) | | | 11,010 | | | — |
| Inventory | | 70,094 | | 62,605 | ||
| Prepaid manufacturing | | 11,636 | | 23,657 | ||
| Other prepaids and current assets | | 11,532 | | 11,099 | ||
| Total current assets | | 341,583 | | 475,631 | ||
| Property and equipment, net | | 2,837 | | 5,119 | ||
| Inventory, non-current | | 43,776 | | 67,495 | ||
| Intangible assets, net | | 53,646 | | 71,673 | ||
| Other assets, non-current | | 6,691 | | 9,686 | ||
| Total assets | | $448,533 | | $629,604 | ||
| | | | | | | |
| Liabilities and Stockholders’ Deficit | | | ||||
| Current liabilities: | | | ||||
| Accounts payable | | $28,456 | | $35,219 | ||
| Accrued rebates, fees and reserves | | 164,867 | | 169,645 | ||
| TSA payables and other accrued liabilities (Note 6) | | | 11,026 | | | — |
| Accrued compensation | | 18,344 | | 21,521 | ||
| Accrued and other current liabilities | | 60,288 | | 105,386 | ||
| Total current liabilities | | 282,981 | | 331,771 | ||
| Term loans, non-current | | | 36,698 | | | 246,481 |
| Convertible notes | | | 228,229 | | | 226,888 |
| Lease liabilities, non-current | | 3,286 | | 5,328 | ||
| Other liabilities, non-current | | 29,329 | | 12,561 | ||
| Total liabilities | | 580,523 | | 823,029 | ||
| Commitments and contingencies (Note 9) | | | ||||
| Stockholders’ deficit: | | | ||||
| Preferred stock ($0.0001 par value; shares authorized: 5,000,000; shares issued and outstanding: 0 at December 31, 2024 and 2023) | | | | | | |
| Common stock ($0.0001 par value; shares authorized: 300,000,000; shares issued and outstanding: 115,614,548 and 112,215,260 at December 31, 2024 and 2023, respectively) | | 12 | | 11 | ||
| Additional paid-in capital | | 1,419,266 | | 1,386,312 | ||
| Accumulated other comprehensive loss | | (275) | | (248) | ||
| Accumulated deficit | | (1,550,993) | | (1,579,500) | ||
| Total stockholders' deficit | | (131,990) | | (193,425) | ||
| Total liabilities and stockholders’ deficit | | $448,533 | | $629,604 | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.